Fate Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-26.4% -$491K
$1M
R&D↓-24.4% -$8M
$25M
D&A↓-36.4% -$2M
$3M
Operating Income↑+33.7% +$18M
$-35M
EBITDA↓-36.4% -$2M
$3M
Interest Expense
—
Interest Income↓-42.7% -$2M
$2M
Net Income↑+32.4% +$15M
$-32M
Operating Margin↓-291.2pts
-1995.1%
Net Margin↓-301.4pts
-1852.4%
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
7.6%
Operating Lease Cost↓-17.8% -$1M
$7M
Revenue YoY Variation↓-37.4pts
-26.4%
Income YoY Variation↑+35.8pts
33.7%
Revenue QoQ Variation↑+18.1pts
-21.4%
Income QoQ Variation↑+22.2pts
6.0%